Looks like $DMTK has added more details/information to their LuminateDNA.com website. I expect this product to launch in the second half of 2021.
LuminateDNA will help tens of millions of people around the world get a DNA skin analysis.
According to the recent $DMTK investor presentation the company believes Luminate could be their biggest product.
Just like their PLA/PLA+ products $DMTK is using their non-invasive genomics smart patch to remove skin cells...
Then those patches are send to their processing lab...
Then the doctor/dermatologist/patient receives a report...
With recommends on how to protect and repair your skin...
$DMTK will also have the ability to use the data collected through LuminateDNA to partner with drug companies and skincare companies to develop better, more effective products based on actual DNA skin data.
Even though John Dobak, CEO of @DermTech told me they intend to sell Luminate through dermatology partners it's unclear from the website whether or not that's still the plan. I believe it is but DTC with telemedicine is another great option
• • •
Missing some Tweet in this thread? You can try to
force a refresh
$DMTK (my second biggest position) is up 16% pre-market on reports that Cigna has offered positive support for $DMTK's PLA/PLA+ genomics patches for early melanoma detection
Cigna is one of the largest insurance companies in the world with 180+ million customers in 30 countries
This news about CIGNA was most likely made possible with two recent events which I already highlighted:
Another thing to note is that UnitedHealth Group also uses OptumInsight for their data/studies so it's very possible we see $UNH provide support for $DMTK's PLA/PLA+ patches as well as their next two products: Luminate and Carcinome
Yesterday I spoke for 55 minutes on @TwitterSpaces hosted by @WOLF_Financial about the markets, my favorite stocks, short selling and a bunch of other stuff.
I have no idea why $DMTK is down 14% today -- makes no sense. There is no news.
Volume is not that heavy and short interest is up to 25% so the bears/shorts are clearly running the show.
$DMTK is still one of my highest conviction stocks for the next 3-5 years. Adoption with dermatologists will be slow, just like it is for most new technologies but eventually $DMTK will be the standard of care. Dermatologists will use the patch before they use the scalpel.
I still believe $DMTK has enormous upside over the next 5+ years.
Don't forget that PLA is just their first product, they have more genomics smart patches coming to market later this year and next year that should be 10x bigger than the PLA product for melanoma detection.
These are tough days for growth investors but also why it's important to keep some perspective.
If you're a long term investor don't let a few days/weeks derail you from your investment strategy.
You'll never achieve big returns if you can't handle some pullbacks along the way.
Whenever my growth stocks pullback I tend to get more concentrated in my favorite positions where I have the most conviction. This doesn't always pay off but it's what works for me.
It's important for every investor to figure out how you want to manage through volatility.
Generally speaking, I think most investors are better off not micromanaging their portfolio or timing the markets because none of us are smart enough to do it well on a consistent basis.
I wanted to share something about @CelsiusOfficial ($CELH) that I learned a couple days ago when talking to a beverage industry expert.
I've been explaining over the past month that $CELH is transitioning from DTR (direct to retailer) to DSD (direct story delivery).
On the last earnings call the CEO of $CELH shared that they now have agreements with 150+ regional DSD partners. I've been wondering how they got to such a large number so quickly and I finally found out why.
Last year when $PEP acquired Rockstar for $3.8 billion they did so because they were locked up in an exclusive distribution agreement and it was the only way out. Rockstar is a dying brand but $PEP wanted some optionality.